News tagged with appetite suppressant

Cometriq approved for rare thyroid cancer

(HealthDay)—Cometriq (cabozantinib) has been approved by the U.S. Food and Drug Administration to treat modullary thyroid cancer that has spread to other parts of the body, the agency said Thursday.

Nov 29, 2012
popularity0 comments 0

Subscribe to rss feed